IRadimed Corporation (IRMD) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 2 analysts19.7% Below Target
IRMD trades 19.7% below Wall Street's consensus target of $120.00.
Current Price$100.24
Average Target$120.00
Low$120.00
Median$120.00
High$120.00
Analyst Target Range
Forward P/E48.3x
(Growth Premium)
PEG Ratio0.65
(Undervalued)
Implied Growth+13.1%
(Moderate)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes IRMD achieves its forward estimates and maintains a stable P/E multiple of 48.3x. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
IRMD Price Target Analysis
Updated July 8, 2026As of July 8, 2026, IRadimed Corporation (IRMD) has a Wall Street consensus price target of $120.00, based on estimates from 2 covering analysts. With the stock currently trading at $100.24, this represents a potential upside of +19.7%. The company has a market capitalization of $1.28B.
Analyst price targets range from a low of $120.00 to a high of $120.00, representing a 0% spread in expectations. The median target of $120.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IRMD trades at a trailing P/E of 57.3x and forward P/E of 48.3x. The forward PEG ratio of 0.65 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +13.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $98.86, with bear and bull scenarios of $62.28 and $130.26 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+43.2%
Industry Consensus
Avg Forward P/E
18.2x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LNTHLantheus Holdings, Inc. | $6.7B | $103.41 | $108.50 | +4.9% | Buy | 19.3x | 17 |
 PRCTPROCEPT BioRobotics Corporation | $1.2B | $21.03 | $31.60 | +50.3% | Buy | — | 15 |
 ANGOAngioDynamics, Inc. | $540M | $13.07 | $16.50 | +26.2% | Hold | — | 11 |
 NVCRNovoCure Limited | $2.0B | $17.72 | $33.00 | +86.2% | Buy | — | 15 |
 GEHCGE HealthCare Technologies Inc. | $29.5B | $64.89 | $81.00 | +24.8% | Buy | 13.3x | 18 |
 STESTERIS plc | $20.8B | $212.30 | $269.50 | +26.9% | Buy | 20.8x | 13 |
 MMSIMerit Medical Systems, Inc. | $4.3B | $72.14 | $94.20 | +30.6% | Buy | 17.7x | 14 |
 INVAInnoviva, Inc. | $1.6B | $22.25 | $37.00 | +66.3% | Buy | 6.2x | 10 |
 ATECAlphatec Holdings, Inc. | $1.4B | $9.38 | $18.00 | +91.9% | Buy | 29.3x | 18 |
 SYKStryker Corporation | $120.1B | $313.38 | $387.46 | +23.6% | Buy | 20.9x | 51 |
IRMD — Frequently Asked Questions
Quick answers to the most common questions about buying IRMD stock.
What is the IRMD stock price target for 2026?
IRadimed Corporation (IRMD) has a consensus 12-month price target of $120, implying 19.7% upside from $100.24. The 2 analysts covering IRMD see moderate appreciation potential.
Is IRMD a buy, sell, or hold?
IRMD has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $120 implies 19.7% upside from current levels.
Is IRMD stock overvalued or undervalued?
At a forward P/E of 48.3084x, IRMD trades at a premium valuation. The consensus price target of $120 (19.7% upside) suggests analysts still see growth justifying the multiple.
How high can IRMD stock go?
The most bullish Wall Street analyst has a price target of $120 for IRMD, while the most conservative target is $120. The consensus of $120 represents the median expectation. Our quantitative valuation model projects a bull case target of $130 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover IRMD stock?
IRMD is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the IRMD stock forecast?
The 12-month IRMD stock forecast based on 2 Wall Street analysts shows a consensus price target of $120, with estimates ranging from $120 (bear case) to $120 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $99, with bear/bull scenarios of $62/$130.
What is IRMD's fair value based on fundamentals?
Our quantitative valuation model calculates IRMD's fair value at $99 (base case), with a bear case of $62 and bull case of $130. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.
What is IRMD's forward P/E ratio?
IRMD trades at a forward P/E ratio of 48.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 57.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy IRMD stock?
Wall Street analysts are optimistic on IRMD, with a "Buy" consensus rating and $120 price target (19.7% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do IRMD price targets vary so much?
IRMD analyst price targets range from $120 to $120, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $120 consensus represents the middle ground. Our model's $62-$130 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare